INTEGRATED SOLUTIONS FOR IMMUNO-ONCOLOGY DRUG DEVELOPMENT

As new advances in cancer immunotherapies are rapidly emerging, drug development must keep pace to meet demands in all phases of the process. That’s why we’ve created integrated solutions to promote collaborative opportunities and support innovative treatments in their journey across the continuum from drug discovery to commercialization.

WITH FOCUSED, SPECIALIZED IMMUNO-ONCOLOGY SERVICES OFFERED WITHIN A GLOBAL CRO INFRASTRUCTURE, YOU’LL BE ABLE TO:

▶ Work with animal models to determine safety and efficacy

▶ Apply innovative approaches to your clinical trials design and execution

▶ Use comprehensive biomarker and companion diagnostics services to enable the delivery of precision medicine

▶ Capitalize on proprietary analytical tools and platforms You’ve identified your future prospect. Now, let us help you reveal your promising molecule’s full potential.

Covance Oncology Trials by Country 2010 – Present

■ Americas

■ EMEA

■ ASIA PACIFIC

ADVANCED SCIENCE REQUIRES AN ADVANCED APPROACH

LEVERAGE SCIENTIFICCONTINUITY

DELIVER PRECISION MEDICINE

RUN MORE EFFICIENT TRIALS

MAXIMIZE YOUR VALUE

Partner with a dedicated team of scientific, medical, regulatory and operational experts to rapidly drive your journey across key milestones from early development through commercialization and to optimize your timelines.

Identify likely responders and apply more efficient treatment selection with our combined LabCorp and Covance capabilities to get support in the development of new candidate biomarkers and companion diagnostic assays.

Gain a competitive edge in your selection of key immuno-oncology sites and patient enrollment with our proprietary knowledgebase, and leverage capabilities to lower risk and improve trial control, all within Xcellerate® Clinical Trial Optimization®.

Maximize market access by demonstrating the full benefit of your oncology product through developing, synthesizing and communicating compelling evidence to your key payer decision-makers.

IMMUNO-ONCOLOGY EXPERIENCE AND STUDY EXECUTION

The mechanisms of action of immunotherapy drugs have very specific consequences for trial planning and conduct. We believe that insight into these challenges is critical in order to create a customized approach to study execution. Here are some important considerations:

▶ Immunotherapies have demonstrated that unleashing T cell activation can generate unique patient adverse events.

▶ Immunotherapies may cause an apparent tumor growth before tumor shrinkage occurs.

▶ Immunotherapies may be more effective in patients who have a particular biomarker immune pattern.

Consequently, management of immuno-oncology trials requires specialized experience and capabilities. Covance and LabCorp have both to cover all your needs for successful trial conduct.

YOUR COMPLETE PARTNER

Fragmented support may address your short-term needs, but true efficiencies are realized when you work with a partner that evaluates your goals from end to end. Let’s work together to advance your strategy and map a more productive path to success.

Learn more about our drug development solutions at www.covance.com

Covance Inc., headquartered in Princeton, NJ, USA, is the drug development business of Laboratory Corporation of America Holdings (LabCorp). COVANCE is a registered trademark and the marketing name for Covance Inc. and its subsidiaries around the world.

The Americas + 1.888.COVANCE + 1.609.452.4440Europe / Africa +00 800.2682.2682 Asia Pacific + 800.6568.3000

© Copyright 2016 Covance Inc.BROCDS044-0116

Drawing on our immuno-oncology and oncology experience spanning hundreds of trials and dozens of indications across our global network, we can apply expert insights to ensure that your study design and execution address your immunotherapeutic’s unique mechanism of action and incorporate the appropriate clinical endpoints.

Our team can even help you identify combination partners and additional indications to strengthen your overall immuno-oncology portfolio. Learn more about how our comprehensive, fully integrated solutions can deliver more value to your immuno-oncology program.

TOGETHER, LET’S REVEAL NEW OPPORTUNITIES FOR YOUR IMMUNO-ONCOLOGY DEVELOPMENT JOURNEY